The latest price target for Y-mAbs Therapeutics (NASDAQ:YMAB) was reported by HC Wainwright & Co. on January 13, 2025. The analyst firm set a price target for $22.00 expecting YMAB to rise to within 12 months (a possible 255.41% upside). 19 analyst firms have reported ratings in the last year.

The latest analyst rating for Y-mAbs Therapeutics (NASDAQ:YMAB) was provided by HC Wainwright & Co., and Y-mAbs Therapeutics reiterated their buy rating.

The last upgrade for Y-mAbs Therapeutics Inc happened on May 10, 2023 when Wedbush raised their price target to $13. Wedbush previously had a neutral for Y-mAbs Therapeutics Inc.

The last downgrade for Y-mAbs Therapeutics Inc happened on April 3, 2023 when Guggenheim changed their price target from N/A to N/A for Y-mAbs Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Y-mAbs Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Y-mAbs Therapeutics was filed on January 13, 2025 so you should expect the next rating to be made available sometime around January 13, 2026.

While ratings are subjective and will change, the latest Y-mAbs Therapeutics (YMAB) rating was a reiterated with a price target of $22.00 to $22.00. The current price Y-mAbs Therapeutics (YMAB) is trading at is $6.19, which is out of the analyst’s predicted range.